FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indic…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
Managed Healthcare Executive

FDA Approves First Subcutaneous Version of Keytruda for Adults With Most Solid Tumors

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The Chosun Ilbo on MSN

Keytruda Subcutaneous Injection Receives FDA Approval

The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged.
조선일보

Alteogen technology helps Merck win FDA approval for subcutaneous Keytruda injection

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing ...

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Hea…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s ...

FDA approves subcutaneous Tremfya induction treatment for ulcerative colitis

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
Managed Healthcare Executive

FDA Approves Subcutaneous Induction of Tremfya for Ulcerative Colitis Patients

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...
Healio

FDA approves Tremfya for subcutaneous induction in adults with ulcerative colitis

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneou…

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of ...
CURE

FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.